Developing Recombinant (r)ZKPr1 for Reducing both General Obesity, Excess Visceral Fat, and Related Metabolic Disorders
In a representative experiment, mice, variably fed high fat diet (HFD) and standard diet (SD) as shown in the Table below, orally received every 4th day rZKPr1 (0.20mg/4 ml water) during the second part of the experiment. In addition to its strong effects on excess visceral fat, rZKPr1 also practically normalized body weight when already obese mice were reverted to SD with added olive oil (SD/OO) during the treatment (without changing food intake). Olive oil helps passage of 14-18% of rZKPr1 through the stomach without adding to body weight. Systemic (i.v., s.c.) rZKPr1 had similar effects.
Related Metabolic Effects of Oral rZKPr1 in Obese Mice in Various Experiments:
- High Blood Glucose (9.5-11 mM): Reduction by 70-80%.
- High Serum Insulin (average: 278 pmol/L): Reduction by ~90-95%.
- High Triglyceride (average: 2.75 mM): Reduction by ~90-95%.
- High Total Cholesterol (average: 3.34 mM): Reduction by 50-60%.
- High LDL-Cholesterol (average: 1.63 mM): Reduction by 50-60%.
- Reduced Muscle Proteins (average:~18.6%): Reduction of protein loss by 80-90%.